ClinicalTrials.gg
RecruitingNCT07722494Updated Aug 10, 2026

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

A Phase 3 interventional study of IBI363 + bevacizumab and Investigator's choice of therapy in Colorectal Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 231 studies testing bevacizumab in Colorectal Neoplasms — 50 open to participants now, 62 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
17th of 225
550 · median 62
Started
2026
with 12 others
Phase 3
42 of 231
4 open now
Primary completion
2028-10
later than 51 of 61 live
Registered
229th of 231
by date

Among the 231 studies testing bevacizumab in Colorectal Neoplasms, this one is the 17th largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2026, is one of 42 in phase 3, reaches primary completion later than 51 of the 61 other live ones, and was the 229th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

50 of the 231 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

45 more — sign in →

By country, each count listing its studies:

All 50 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the written Form and is capable of complying with the visit schedules and relevant procedures specified in the protocol.
  2. Aged ≥ 18 years, with no restriction on gender.
  3. or cytologically confirmed unresectable colorectal adenocarcinoma.
  4. Has experienced treatment failure or intolerance to prior systemic standard therapies administered for metastatic disease, with failure or intolerance occurring on the most recent .
  5. Has at least one per Version 1.1 (RECIST v1.1).
  6. Colorectal cancer characterized by proficient mismatch repair (pMMR), or microsatellite stable (MSS) status.
  7. Confirmed adequate bone marrow and organ function at screening.
  8. Performance Status (ECOG PS) score of 0 or 1.
  9. Expected survival duration ≥ 3 months.
  10. Female subjects of , or male subjects whose partners are females of childbearing potential, agree to strictly use effective measures throughout the treatment period and for 6 months after treatment completion. Lactating female subjects agree to completely refrain from breastfeeding throughout the treatment period and for 6 months after treatment completion.

Exclusion criteria

Exclusion Criteria

  1. Prior disease progression, treatment intolerance, or to all three agents: fruquintinib, trifluridine/tipiracil (TAS-102), and regorafenib.
  2. Prior receipt of immunotherapy targeting anti-PD-(L)-1 or in the setting.
  3. History of severe toxicities related to anti-PD-(L)-1 immunotherapy or anti-VEGF therapy that necessitated permanent discontinuation of treatment, or contraindication to any of the above agents.
  4. Prior administration of interleukin (IL)-2 or IL-15 cytokines.
  5. Absence of documented clear evidence to confirm left- or right-sided primary colorectal tumor; or presence of primary colorectal lesions on both sides.
  6. Radiologically confirmed active or symptomatic central nervous system (CNS) metastases, including intraparenchymal brain, , and spinal cord metastases.
  7. Subjects with unresolved adverse events attributable to any prior anti-tumor therapy that have not recovered to (Version 5.0) Grade 0 or Grade 1, or returned to baseline levels prior to randomization. Exceptions include alopecia, fatigue, hypothyroidism managed solely with thyroid hormone replacement, hyperglycemia controlled exclusively by insulin replacement, electrolyte abnormalities manageable with symptomatic treatment only, and other conditions judged by the Investigator to pose no safety risks with study drug administration.
  8. History of another malignant tumor within 5 years before the first dose of study drug. The following are allowed if curatively resected, with no current evidence of residual or recurrent disease and an extremely low recurrence risk: carcinoma in situ, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, lentigo maligna, localized prostate cancer, papillary thyroid carcinoma, non-invasive papillary urothelial carcinoma.
  9. Active disease requiring systemic therapy (e.g., disease-modifying anti-rheumatic drugs, , ) within 2 years prior to the first study drug dose. Replacement therapies (e.g., thyroxine, insulin, physiological corticosteroids for adrenal or pituitary insufficiency) shall not be regarded as systemic immunosuppressive treatment.
  10. Prior history of interstitial lung disease, pulmonary fibrosis, pneumoconiosis, drug-induced pneumonitis, radiation pneumonitis, or other pulmonary disorders requiring corticosteroids or other therapeutic intervention.
  11. Active uncontrolled bleeding or known bleeding diathesis;
  12. Known history of allogeneic solid organ transplantation or hematopoietic stem cell transplantation.
  13. Subjects with known or suspected to the study drug or any of its .
  14. Female subjects who are pregnant, breastfeeding, or planning to conceive before study drug administration, during treatment, or within 6 months after the last study drug dose.
  15. Any past medical condition, prior treatment, or abnormal laboratory findings, or current clinical evidence that, in the Investigator's judgment, may compromise subject safety, interfere with the acquisition of , impair subject compliance, or confound the safety evaluation of the study drug; subjects with psychiatric disorders, altered mental status, or substance abuse that impairs the ability to comprehend the informed consent process and/or complete required study assessments; subjects whom the Investigator determines will fail to comply with protocol requirements for known or foreseeable reasons.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    IBI363 plus bevacizumab

    IBI363 in combination with bevacizumab in participants with advanced colorectal cancer who have failed or are intolerant to standard care of therapy

    Drug: IBI363 + bevacizumab

  • Active comparator
    Investigator's choice of therapy

    Investigator's choice of therapy in participants with advanced colorectal cancer who have failed or are intolerant to standard care of therapy

    Drug: Investigator's choice of therapy

Interventions

  • DrugIBI363 + bevacizumab

    Drug pages: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 · Bevacizumab

    In this arm, patients will receive IBI363 plus bevacizumab

  • DrugInvestigator's choice of therapy

    In this arm, patients will receive Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafenib

    Also known as: Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafenib

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the date of randomization until the date of death from any cause

    Time frame: Through out the study (an average of 2 years)

Secondary outcomes

  1. AE( Adverse event)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  2. TEAE( Treatment emergent adverse event)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  3. irAE(Immune-related AE)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  4. SAE(Serious adverse event)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  5. AESI(Adverse Event of Special Interest)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  6. progression-free survival (PFS)

    PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause, whichever occurs first

    Time frame: Through out the study (up to 2 years)

  7. Objective response rate (ORR)

    ORR is defined as the proportion of participants in the analysis set who achieve a confirmed objective response (complete response \[CR\] or partial response \[PR\])

    Time frame: Through out the study (up to 2 years)

  8. disease control rate (DCR)

    DCR is defined as the proportion of participants with a complete response (CR) or partial response (PR) or stable disease (SD)

    Time frame: Through out the study (up to 2 years)

  9. time to response (TTR)

    TTR is defined as the time from the date of randomization to the date of first documented tumor response (CR/PR)

    Time frame: Through out the study (up to 2 years)

  10. duration of response (DoR)

    DoR is defined as the time from the date of first documented tumor response (CR/PR) until progression or death due to any cause, whichever occurs first.

    Time frame: Through out the study (up to 2 years)

  11. Half-life (T1/2) of IBI363

    PK(Pharmacokinetics) parameters half-life (t1/2) of IBI363

    Time frame: Up to 2 years

  12. Clearance (CL) of IBI363

    PK parameters clearance rate of IBI363

    Time frame: Up to 2 years

  13. Volume of distribution (V) of IBI363

    PK parameters apparent volume of distribution(V) of IBI363

    Time frame: Up to 2 years

  14. Immunogenicity of IBI363

    Incidence of anti-IBI363 anti-drug antibodies (ADAs) and/or neutralizing antibodies (NAbs)

    Time frame: Up to 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 27 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722494
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 31, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 10, 2026

Study contacts

binbin Min
Contact
bingo.min@innoventbio.com
0512-69566088
Kefeng Ding, Medical Doctor
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine
Tao Zhang, Medical Doctor
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ying Yuan, Medical Doctor
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 · Bevacizumab

Start the discussion